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Background We report the first study that analyses public and phil-
anthropic investments awarded to UK institutions for research relat-
ed to sexually transmitted infections (STIs).
Methods We systematically searched award data from the major 
funders for information on all infectious disease research funding 
awarded in 1997–2013. The STI–related projects were identified and 
categorised by pathogen, disease and type of science along the re-
search pipeline from preclinical to translational research.
Findings We identified 7393 infection–related awards with total in-
vestment of GBP 3.5 billion. Of these, 1238 awards (16.7%) covering 
funding of GBP 719.1 million (20.5%) were for STI research. HIV as 
an STI received GBP 465 million across 719 studies; non–HIV STIs 
received GBP 139 million across 378 studies. The Medical Research 
Council provided greatest investment (GBP 193 million for HIV, GBP 
45 million for non–HIV STIs). Preclinical awards totalled GBP 233 
million (37.1%), whilst translational research received GBP 286 mil-
lion (39.7%). Substantial proportions of HIV investment addressed 
global health research (GBP 265 million), vaccinology (GBP 110 mil-
lion) and therapeutics (GBP 202 million). For other STIs, investments 
focused on diagnostics (GBP 45 million) and global health (GBP 27 
million). Human Papilloma Virus research received GBP 58 million 
and chlamydia GBP 24 million. Funding for non–HIV STIs has de-
clined in the three most recent years of this data set.
Conclusions The investment for HIV research awarded to UK insti-
tutions correlates with the high global burden, but other STIs are rel-
atively neglected, including gonorrhoea and syphilis. Future STI 
funding should be better aligned with burden while addressing the 
emerging risk of antimicrobial resistance in Neisseria gonorrhoeae and 
outbreaks of other pathogens.
Sexually transmitted infections (STIs) are responsible for a large global 
burden of disease, of which HIV is individually the pathogen of great-
est public health impact. In 2010, HIV accounted for 81.5 million dis-
ability–adjusted life years (DALYs), 3.3% of the global burden [1], 
whilst revised figures suggested an estimated 1.3 million deaths from 
HIV in 2013 [2].
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There are approximately 500 million transmissions of STIs 
(other than HIV) worldwide annually, whilst seropreva-
lence of herpes simplex virus is highest in Africa, with in-
fection found in 30–80% of women and 10% to 50% of 
men [3]. In the UK, high–risk human papilloma virus in-
fection was detected in 15.9% of women [4]. Chlamydia is 
the most commonly diagnosed STI in England with over 
200 000 new diagnoses in 2012 [5]. Stillbirth and neonatal 
damage due to congenital syphilis are thought to rival the 
early life burden of HIV infection, though arguably syphilis 
receives far less attention [6]. Incidence of syphilis is rising 
in many countries, including the UK and China [7,8]. 
There are over 100 million new cases of gonorrhoea glob-
ally each year [9], and incidence is also increasing in Eng-
land [5]. The extent of observed antimicrobial resistance 
patterns has led to concerns that gonorrhoea will soon be-
come untreatable [9,10]. Viral hepatitis and infection with 
Mycoplasma genitalium are further infections that add to the 
overall burden of STIs.
One tool in developing policies that attempt to better pre-
vent, manage and treat all STIs is investment in research. 
Funding covers all types of science along the R&D research 
pipeline from pre–clinical to operational and implementa-
tion research. UK institutions have received an estimated 
GBP 2.6 billion of public and charitable funding to carry 
out infectious disease research between 1997 and 2010 
[11], and estimates suggest the UK ranks second globally 
in terms of the amount of research and development (R&D) 
funding for neglected infectious disease research [12]. 
There are also 38 UK institutions in the most recent rank-
ings list of the ‘top 100 most global universities’ [13]; thus 
there is a large quantity of research funding available for 
analysis coming from institutions carrying out relevant 
global activity. We report here on the funding for STI–re-
lated research awarded to UK institutions in 1997–2013, 
including three further years of investment data as part of 
an update on the previous work [11].
We identify probable areas of research strength and pos-
sible investment gaps in relation to global sexual health that 
will be of relevance to policy–makers, funders and re-
searchers, and then briefly discuss how new approaches 
might help with managing burdens and allocating existing 
resources to the most appropriate preclinical, intervention-
al or observation studies.
METHODS
We analysed infectious disease–related studies funded over 
a 17–year period (1997–2013 inclusive) and awarded to 
UK institutions, and identified those relevant to STI re-
search. Global health studies were defined as those which 
investigated diseases not endemic in the UK, or where the 
study had a clear reference to another country (eg, HIV in 
South Africa). We excluded open–access data from the 
pharmaceutical industry as it was limited and not repre-
sentative.
The methods have been described in detail previously [11], 
and also to some extent replicated on the study website 
[14] and in other study publications [15-17]. The over-
arching data set was constructed by approaching the major 
sources of public and charitable funding for infectious dis-
ease research studies, including the Wellcome Trust, Med-
ical Research Council and other research councils, UK gov-
ernment departments, the European Commission, Bill and 
Melinda Gates Foundation, and other research charities. 
Funders were identified by searching databases such as the 
National Research Register (now archived, ref. [18]), or 
Clinicaltrials.gov, authors knowledge of the funding land-
scape, through the knowledge of the Infectious Disease Re-
search Network (www.idrn.org) and through searches of 
the internet. Where available, the funding decisions listed 
on their website were searched for infectious disease re-
search awards (eg, Wellcome Trust); otherwise, the funder 
was directly approached and asked to provide information 
on their infection–related awards.
Each study was screened for relevance to infectious disease 
research and assigned to as many disease categories as ap-
propriate. These included area of microbiology (bacteriol-
ogy, virology, parasitology, mycology) and cross–cutting 
themes such as global health and antimicrobial resistance, 
as well as awards relating to new tools and products such 
as diagnostics, therapeutics and vaccines. The categories 
were selected based on author discussions during and since 
the data set was developed. Studies were also allocated to 
one of four categories (initially for 1997–2010 data) along 
the R&D pipeline: pre–clinical; phase 1, 2, or 3; interven-
tion and product development; and translational research. 
For 2011–2013 data only, a fifth category has been added, 
this being cross–disciplinary, and is defined as a study sig-
nificantly covering two types of science along the R&D 
pipeline (as per our categorisation above, also see ref. [14]. 
This category was added in response to a seemingly in-
creasing number of awards involving consortia or pro-
gramme grants that transcend the research pipeline bound-
aries of this study. The 1997—2010 data has not yet 
retrospectively been assessed for cross–disciplinary studies 
(capacity for a significant retrospective analysis of the en-
tire initial data set is limited). The major funders were con-
sidered separately, while others were grouped into catego-
ries, such as professional bodies and societies, or other 
research charities. A total of 26 funder categories were 
used. All categorisation was carried out by author MGH, 
with provisional data sets circulated to authors for review 
and comment. Author JRF further verified a random sam-
ple of 10% of the 1997—2010 data set, whilst JRF and fur-
December 2015  •  Vol. 5 No. 2 •  020405	 2	 www.jogh.org •  doi: 10.7189/jogh.05.020405
V
IE
W
PO
IN
TS
PA
PE
RS
UK investments in sexually transmitted infection research, 1997–2013
ther external colleagues carried out similar process for 
2011–2013 data. Author agreement was measured by a 
Kappa score (0.95 and 0.91) and differences settled by con-
sensus. We excluded studies not immediately relevant to 
infection, veterinary infectious disease research studies (un-
less there was a clear zoonotic component), and studies 
which included UK collaborators, but where the funding 
was awarded to a non–UK institution. Unfunded studies 
were also excluded. Grants awarded in a currency other 
than pounds sterling were converted to UK pounds using 
the mean exchange rate in the year of the award. All awards 
were adjusted for inflation. Relative levels of investment 
were presented via a ‘GBP per disability–adjusted life years’ 
(DALY) figure; this represented the total investment in re-
search per 1 DALY. The DALY figures were extracted from 
the 2010 Global Burden of Disease study [1].
This analysis includes HIV as an STI. Since sexual trans-
mission of HIV is in most settings overwhelmingly the most 
common route, we included HIV–related studies as STI–
related unless they specifically addressed other transmis-
sion modes. Therefore, studies investigating HIV via verti-
cal transmission or via bloodborne pathways were 
excluded. Similarly, where other pathogens have multiple 
modes of transmission, eg, hepatitis B, they were only in-
cluded if transmission by sexual contact were explicitly 
stated in the study title or abstract. Data management was 
carried out in Microsoft Excel and Access (versions 2007 
and 2013) and statistical analysis with Stata (version 13).
RESULTS
A total of 7393 awards were identified as relevant to all in-
fectious diseases across 1997–2013 with a total investment 
of GBP 3.5 billion. Of these, 1238 awards (16.7%) were 
identified as relevant to STI research, with total funding of 
GBP 719.1 million (20.5% of all infectious disease funding; 
Table 1). Some top–level data reproduced here have been 
previously published as 1997–2010 results in an overview 
of all infectious disease funding (specifically study numbers 
and total funding for HIV including non–STI transmis-
sions, gonorrhea, syphilis, chlamydia, HPV and HSV) [11]. 
There was one pre–clinical study in 2003 focusing on 
Trichomonas vaginalis.
Of this, GBP 596.8 million (83.0%) was related to HIV 
across 873 studies (70.5%), and GBP 155.6 million 
(21.6%) was invested in other STIs over 378 studies 
(32.5%). Median study funding for HIV research was GBP 
173 109 (IQR GBP 39 374–454 801); median study fund-
ing for other STIs was GBP 105 115 (IQR GBP 17 827–
251 356). A wide variety of funders contributed greatly to 
the sum funding, but the Medical Research Council invest-
ed the greatest amount for both HIV (GBP 192.8 million, 
32.0%) and for other STIs (GBP 45.2 million, 29.0%). An-
nual funding is volatile with no consistent temporal trend 
in funding awards for either HIV or other STI research, and 
it appears as though funding for non–HIV STIs is declin-
ing in the most recent years of this data set (Figure 1).
For HIV research, pre–clinical science received GBP 247.8 
million (41.5%) across 358 studies, phase I to III trials GBP 
110.6 million (18.5%) across 62 studies, product develop-
ment research GBP 32.9 million (5.5%) across 55 studies, 
and implementation and operational research GBP 194.4 
million (32.6%) across 397 studies; there were also one 
cross–disciplinary study awarded between 2011–2013 (Ta-
ble 2). For other STIs, pre–clinical science received GBP 
35.9 million (23.1%) across 123 studies, phase I to III tri-
als GBP 0.6 million (0.4%) across 4 studies, product devel-
opment research GBP 12.0 million (7.7%) across 27 stud-
Table 1. Total funding, mean and median award size of HIV and other sexually transmitted infections (STI) research awarded 
1997–2013
Disease Number 
of stuDies
PerceNtage 
of sti stuDy 
Number (%)*
total fuNDiNg 
(gbP)
PerceNtage 
of sti fuND-
iNg (%)*
meaN awarD, gbP 
(sD)
meDiaN awarD, gbP (iQr) toP fuNDer, millioNs (%)
All STI studies 1238 n/a 719 086 641 n/a 580 845 (1 925 725) 144 138 (33 247–365 209) MRC, 284.4 (39.5)
Non–HIV STIs 402 32.47 155 630 214 21.64 387 139 (965 424) 105 115 (17 827–251 356) MRC, 45.2 (29.0)
HIV 873 70.52 596 800 543 82.99 66 3534 (2 213 359) 173 109 (39 374–454 801) MRC, 192.8 (32.0)
Chlamydia 119 9.61 24 485 887 3.41 205 763 (556 606) 60 212 (11 450–180 498) UK government depart-
ment, non–DH, 9.6 (39.2)
Gonorrhoea 20 1.62 1 388 703 0.19 69 435 (96 071) 13 968 (3699–144 980) Wellcome, 0.46 (33.3)
Syphilis 5 0.40 1 061 560 0.15 212 312 (152 848) 207 346 (113 088–229 907) Wellcome, 0.57 (53.5)
Candida 87 7.03 29 458 307 4.10 338 601 (445 301) 261 386 (86 394–382 357) BBSRC, 11.3 (38.5)
Mycoplasma 3 0.24 245 667 0.03 81 889 (107 412) 36 409 (46 989–204 559) MRC, 0.20 (83.3)
HPV 164 13.25 58 254 838 8.10 355 212 (811 689) 113 852 (38 476–242 110) Charity, 31.9 (54.8)
Herpes Simplex Virus 10 0.81 2 530 037 0.35 253 003 (381 987) 95 514 (15 682–309 610) Wellcome, 2.0 (78.1)
Viral hepatitis 3 0.24 74 448 0.01 24 816 (24 446) 13 135 (8401–52 911) Other, 0.05 (71.1)
n/a – not applicable, SD – standard deviation; IQR – interquartile range, MRC –Medical Research Council
*Percentages in are calculated as a fraction of all STI research. Because awards can cover more than one disease area or product category, the sum of these 
column percentages do not add up to exactly 100%.
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ies, and implementation and operational research GBP 99.5 
million (64.0%) across 246 studies; Further, there were 
also three cross–disciplinary studies (two for non–HIV 
STIs, and one for HIV research) totalling GBP 18.7 million.
Within HIV research (Table 3), global health–related stud-
ies received GBP 264.9 million (44.4% of HIV research) 
across 228 studies (across all infectious disease, studies 
with a clear global health component represented 36.3% 
of all funding). There was also GBP 109.7 million (18.4%) 
invested in vaccinology, GBP 202.3 million (33.9%) in 
therapeutics and GBP 25.2 million (4.2%) in diagnostics. 
For other STI research, GBP 27.2 million was concentrated 
on global health (17.5% of all non–HIV STI funding), 
across 38 studies. The main focus here was for studies re-
lating to non–pathogen–specific STI research; despite sum 
funding of GBP 24.5 million, there was just one study (GBP 
0.3 million) considering chlamydia in a global context
There was GBP 3.5 million (2.3%) invested in in vaccinol-
ogy research, GBP 3.8 million (2.4%) for therapeutics and 
GBP 44.7 million (28.7%) for diagnostics. Antimicrobial 
resistance–related investments were GBP 20.7 million 
(3.5%) for HIV, and GBP 5.7 million (3.7%) for other STIs.
Figure 1. Investments on HIV (A) and other sexually–transmitted infection (B) research awarded 
to the UK over time and by type of science (x1 HIV and x2 STI cross–disciplinary studies not 
shown here).
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Where data are available and presented, the global burden 
of disease, measured in disability adjusted years (DALYs), 
was correlated with levels of research investment (Table 
4). Time periods were chosen to reflect the years in which 
burden data was available. From 2004 DALYs, there is an 
overall investment of GBP 10.20 per DALY for HIV re-
search, and GBP 14.93 per DALY for other STIs. Further-
more, there was investment of GBP 6.53 per DALY for chla-
mydia research, and relatively less investment in syphilis 
(GBP 0.37) and gonorrhoea (GBP 0.39). Using 2010 bur-
den data, which is the most recent time period for which 
complete burden data was available, the relative invest-
ments against burden are – HIV GBP 7.33, other STIs GBP 
14.18, chlamydia GBP 34.29, syphilis GBP 0.11 and gon-
orrhoea GBP 4.92. Annual investment over time increases 
for HIV research, but noticeably decreases for research of 
other STIs (Figure 1).
DISCUSSION
Our study is the first systematic analysis of research fund-
ing for STI research, including STI–related HIV, awarded 
to UK institutions. Over the 17–year time period of the 
Table 2. Funding of research into HIV and other sexually transmitted infections (STIs) 1997–2013, described by type of science
stuDy tyPe all sti NoN–HiV sti HiV
Pre–clinical:
Study numbers 461 123 358
Funding (GBP) 267 053 431 35 881 994 247 843 494
Phase I – III:
Study numbers 62 4 62
Funding (GBP) 106 983 764 589 207 110 562 571
Intervention & product development:
Study numbers 79 27 55
Funding (GBP) 40 749 294 11 967 782 32 949 526
Translational:
Study numbers 633 246 397
Funding (GBP) 285 593 246 99 542 253 194 387 022
Table 3. Funding of research into HIV and other sexually transmitted infections (STIs) described by general disease theme
Disease Number 
of 
stuDies
total fuNDiNg 
(gbP)
PerceNtage 
of all HiV 
fuNDiNg
meaN awarD, gbP (sD) meDiaN awarD, gbP (iQr) toP fuNDer, millioNs (%)
HIV/AIDS:
Global health 228 264 900 733 44.4% 1 161 845 (3 885 828) 198 934 (53 409–694 934) DFID, 78.9 (29.8)
Vaccinology 70 109 708 029 18.4% 1 567 258 (2 963 178) 558 247 (256 053–1 361 466) European Commission, 29.5 (26.9)
Therapeutics 184 202 317 448 33.9% 1 099 551 (4 089 456) 195 947 (36 809–672 265) European Commission, 60.1 (29.7)
Paediatrics 77 32 503 928 5.4% 422 128 (635 597) 196 270 (47 595–464 190) MRC, 7.6 (44.0)
Diagnostics 41 25 173 418 4.2% 613 985 (1 797 939) 82 787 (14 835–410 458) MRC, 4.3 (17.3)
Antimicrobial resistance 33 20 773 195 3.5% 629 490 (1 775 416) 125 119 (59 327–236 201) European Commission, 8.9 (42.7)
Primary care 19 4 452 155 0.7% 234 323 (401 638) 49 368 (11 333–282 707) Wellcome, 2.7 (61.5)
Economics 7 1 143 190 0.2% 163 312 (134 121) 82 872 (70 853–234 309) Wellcome, 0.4 (30.7)
Behavioural science 20 3 849 174 0.6% 192 458 (122 607) 195 533 (109 439–308 732) MRC, 2.8 (72.2)
Non–HIV sexually–transmitted infections:
Global health 38 27 186 347 17.5% 715 430 (1 184 356) 289 717 (70 843–737 257) DFID, 12.5 (46.1)
Vaccinology 14 3 537 045 2.3% 252 646 (325 470) 116 207 (62 976–237 470) Department of Health, 1.2 (34.6)
Therapeutics 11 3 793 661 2.4% 344 878 (331 566) 242 343 (144 138–320 031) Charity, 2.1 (54.5)
Paediatrics 12 1 217 304 0.8% 101 442 (204 546) 319 72 (14 098–80 664) MRC, 0.7 (60.6)
Diagnostics 123 44 705 952 28.7% 363 463 (931 522) 72 293 (11 793–175 234) Charity, 15.5 (34.5)
Antimicrobial resistance 5 5 741 870 3.7% 1 148 374 (2 472 306) 6470 (776–165 259) DFID, 5.6 (97.0)
Primary care 41 4 988 181 3.2% 121 663 (248 283) 18 389 (11 450–172 042) Department of Health, 2.4 (48.7)
Economics 6 2 573 574 1.7% 428 929 (550 030) 201 856 (131 999–514 066) Department of Health, 2.3 (91.9)
Behavioural science 18 3 260 456 2.1% 181 136 (128 084) 181 211 (98 963–247 826) MRC, 1.8 (56.3)
SD – standard deviation; IQR – interquartile range, MRC – Medical Research Council, DFID – Department for International Development
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Table 4. Comparisons between investment in HIV and other sexually transmitted infections (STIs) research and global burden of 
disease
Disease Number 
of 
stuDies
total fuNDiNg 
(gbP)
Daly 2004 Daly 2010 total iNVestmeNt 
relatiVe to 2004 
burDeN (gbP Per 
Daly)
total iNVestmeNt 
relatiVe to 
2010 burDeN 
(gbP Per Daly)
aNNual iNVestmeNt 
1997–2004 
(gbP)
aNNual 
iNVestmeNt 
2005–2010 
(gbP)
aNNual  
iNVestmeNt 
2011–2013 
(gbP)
HIV 873 596 800 543 5 851 2843 81 457 000 10.20 7.33 30 178 341 37 300 762 43 856 416
non–HIV STIs: 402 155 630 214 10 424 871 10 978 000 14.93 14.18 11 322 986 8 005 387 5 671 334
Chlamydia 119 24 485 887 3 748 198 714 000 6.53 34.29 2 182 799 706 665 927 836
Gonorrhoea 20 1 388 703 3 549 975 282 000 0.39 4.92 96 047 30 004 146 768
Syphilis 5 1 061 560 2 846 113 9 578 000 0.37 0.11 96 930 47 686 0
Candida 87 29 458 307 n/a n/a n/a n/a 1 259 942 2 117 066 2 225 459
Mycoplasma 3 245 667 n/a n/a n/a n/a 5139 34 093 0
HPV 164 58 254 838 n/a n/a n/a n/a 4 489 759 2 723 738 1 998 113
Herpes simplex virus 10 2 530 037 n/a n/a n/a n/a 2 171 198 782 286 1 054 630
Viral hepatitis 3 74 448 n/a n/a n/a n/a 9306 0 0
DALY – disability–adjusted life year, HPV – human papilloma virus, n/a – not applicable
study, there is consistent funding for HIV research along 
the entire research pipeline in all types of science, includ-
ing phase I–III trials. However, this is not replicated for 
other STIs where much research is categorised as transla-
tional research and there are fewer preclinical studies. HIV 
studies are typically larger in size, and HIV received almost 
four times as much funding as other STIs combined. With-
in HIV, global health and therapeutics studies received most 
investment, whilst other STI studies focused on global 
health and diagnostics. Non–HIV STIs broadly experienced 
a decline in annual research investments over time, and 
relative to global burden, syphilis and gonorrhoea are rela-
tively less well funded than HIV and chlamydia. Total fund-
ing per annum is unpredictable.
A global HIV research infrastructure is now well estab-
lished, and this is partly so because of the formation of UN-
AIDS, an over–arching well–funded independent body that 
has successfully encouraged investment, collaborative 
work and sustained political leadership [19,20]. There are 
other groups tracking specific aspects of global HIV re-
search funding [21], so the research gaps may be less obvi-
ous than in other disease areas. Substantial public and phil-
anthropic investments have been directed towards the 
development of an HIV vaccine, shown both within this 
UK analysis here and also in international projects [21]. 
This global quest has proven relatively fruitless so far but 
has potentially very high impact should the goals be 
achieved. Preventive measures may be the most effective 
approach in the long–term, and there are widespread ef-
forts to research and develop microbicides [21] and under-
stand how best to implement effective behaviour change 
[22,23]. Having closely observed the UK portfolio of HIV 
research, it is arguably the large scale behavioural science 
studies that are most lacking by comparison with the USA 
and Global South, as well as how to maximise the effective-
ness of genitourinary medicine clinics and other services 
in primary care that offer HIV testing. Research may also 
focus on gaining a better understanding of how to increase 
testing in high risk groups such as UK men who have sex 
with men, a key population which continues to experience 
HIV incidence comparable with generalised epidemics.
Antimicrobial resistance (AMR) is a global threat, and has 
historically been under–funded in the UK [24]. There have 
been few new antibacterial therapeutics in recent years and 
there are several reasons for this, including the pharmaceu-
tical industry perceiving a lack of return on their invest-
ment compared to long–term chronic illnesses [25] result-
ing in market failure [26]. The levels of resistance in 
Neisseria gonorrhoeae are exceptionally high [9], and the 
organism has long been known for its exceptional ability 
to evolve resistance genes. There is virtually no UK research 
focussing on gonococcal AMR, although clinical trials in 
the US are investigating the potential of Solithromycin, a 
4th generation macrolide with promising results in a phase 
II trial [27]. This is a critical area of potential research focus 
for funders and policymakers to consider, particularly in 
light of the 2014 review of the global economics of AMR 
[28].
The investments into chlamydia research are relatively 
strong when compared with global burdens, but this infec-
tion is the most common STI in the UK [5]. The vast ma-
jority was translational in focus and very little was catego-
rized as global health. It may be that a much larger 
proportion of the research was considered to address local 
needs, as opposed to other infections like HIV with the sig-
nificant emphasis on global health. Much HPV–related re-
search was either pre–clinical in nature or had a focus on 
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diagnostic and screening programmes. This approach may 
well change now that effective vaccines have been imple-
mented into the UK immunisation schedules – modelling 
the effectiveness of vaccine programmes and research into 
increasing uptake and future cervical screening pro-
grammes may now take priority. Syphilis research may best 
centre on areas such as development of a vaccine [29], how 
best to implement behaviour change at the preventive lev-
el and how to ensure access to treatments for those who 
need it. We identified only one study for T. vaginalis, de-
spite its being described as the most common curable STI 
in the world with implications for increased HIV transmis-
sion [30].
It is important that researchers have access to a diverse 
group of funding institutions, to ensure broad based invest-
ments for different areas of STI research, and to increase 
predictability. There is evidence that where public sector 
investment decreases, so does private investment [31]. 
Thus incentives for, and collaborations with, the private 
sector are important for the research environment as a 
whole. New sources of investment would help with the fo-
cus on priority areas. Should greater investment be se-
cured, it will need to be spent wisely on research that clear-
ly adds to the evidence base, does not unnecessarily 
duplicate existing work or knowledge, and will be high im-
pact (measuring impact will vary depending upon the type 
of science addressed in the research). A coordinated proac-
tive approach between existing funders, and international 
co–operations where required, would help further identify 
and fund priority areas, and international systematic anal-
yses similar to that reported here could be replicated to 
provide detailed information on the current and historical 
funding landscape in other countries. Future linkage be-
tween investment and outputs of research such as publica-
tions, impact on policy and products such as databases 
would give some indication of the power and quality of re-
search.
Our study has several limitations, which have been high-
lighted and discussed in detail elsewhere [11]. There was 
little publicly–available data from the pharmaceutical in-
dustry. Hence, there is a data gap particularly in relation to 
funding of clinical trials and the development of vaccines 
and diagnostics, which the pharmaceutical and biotechnol-
ogy industry are mostly financing (the sums of public and 
charitable investment in HIV–related phase I–III trials are 
not replicated across most other disease areas including 
other STIs). Beyond disease burden, other measures, such 
as economic burden should also be utilised when prioritis-
ing limited resources, but little information is available re-
garding the economic impact of STIs. We rely on the orig-
inal data being complete and accurate, and are unable to 
take into account distribution of funds from the lead insti-
tution to collaborating partners or any annualisation of the 
total funding awarded, nor can we assess quantity of each 
award given to overheads or the impact of the introduction 
of full–economic costing. Also, assigning studies to catego-
ries is a subjective and imperfect process – although we 
used at least two researchers to do this to reduce inter–ob-
server error. Our study focuses on UK–led investments – 
we do not know if similar patterns (eg, a lack of public or 
charitably–funded clinical trials in STIs) would also emerge 
if the analysis were repeated for other high–income coun-
tries, and we do not know how globally representative the 
UK investments are against other countries portfolios. We 
have not here measured either the outputs or impact of 
funded research. The assessment against measures of bur-
den used the most comprehensive DALY figures available, 
but they are only estimates and their reliability is not pre-
cisely known; there may also be definitional differences be-
tween data sets and burden data was not available for all 
infections.
This analysis of UK investments in STI research highlights 
some areas of probable research strength, particularly with 
global health–related studies and more generally across the 
HIV research pipeline. It also suggests there are clear gaps 
and a need for greater research into syphilis, gonorrhoea 
and antimicrobial resistance. Work is ongoing to produce 
in–depth analyses of infectious disease research invest-
ments awarded to US institutions, and this will allow com-
parisons with UK strengths and weaknesses and help to set 
benchmarks for assessing investment vs disease burden. 
There is a continuing need to extend beyond this to build 
a global funding database of all types of HIV and other STI–
related research. This analysis can be of use for funders, 
policymakers and researchers and act as a stimulus for tar-
geting priority areas in STI research.
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